NRG-GY009 for Platinum Resistant Ovarian Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to compare good and bad effects of adding atezolizumab to the usual chemotherapy (liposomal doxorubicin) and to the usual chemotherapy with bevacizumab.

What is the Condition Being Studied?

Platinum resistant ovarian cancer

Who Can Participate in the Study?

Adult women age 18 or older, who have:
- recurrent platinum resistant ovarian cancer
- are not pregnant or nursing

Age Group
Adults

What is Involved?

If you agree to be in the study you will:
-Be randomized (put into one of three groups by chance like a flip of a coin) and receive either:
Group 1 - receive an investigational agent
Group 2 - receive an investigational chemotherapy regimen
Group 3 - receive the usual chemotherapy regimen for this type of cancer
- Thyroid testing will be done every cycle
- Echocardiograms of the heart may be done every other cycle
- Pregnancy tests using whole blood

Study Details

Full Title
NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND#134427) versus Peglylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Principal Investigator
Gynecologic Oncologist
Protocol Number
IRB: PRO00091821
NCT: NCT02839707
Phase
Phase II/III
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698